PepGen Inc. (NASDAQ:PEPG - Get Free Report) CEO James G. Mcarthur bought 10,000 shares of PepGen stock in a transaction on Thursday, April 17th. The shares were acquired at an average price of $1.35 per share, for a total transaction of $13,500.00. Following the completion of the acquisition, the chief executive officer now owns 113,913 shares in the company, valued at $153,782.55. This represents a 9.62 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
PepGen Stock Performance
PEPG stock opened at $1.62 on Wednesday. The company's 50 day moving average price is $1.70 and its 200 day moving average price is $3.67. The firm has a market capitalization of $52.96 million, a price-to-earnings ratio of -0.54 and a beta of 1.42. PepGen Inc. has a fifty-two week low of $0.88 and a fifty-two week high of $19.30.
PepGen (NASDAQ:PEPG - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.81) by $0.13. Equities analysts forecast that PepGen Inc. will post -2.73 EPS for the current fiscal year.
Hedge Funds Weigh In On PepGen
Several large investors have recently bought and sold shares of PEPG. RTW Investments LP purchased a new position in shares of PepGen in the 4th quarter valued at about $12,102,000. Northern Trust Corp boosted its holdings in PepGen by 5.4% in the fourth quarter. Northern Trust Corp now owns 157,038 shares of the company's stock valued at $595,000 after purchasing an additional 7,984 shares in the last quarter. Millennium Management LLC raised its holdings in PepGen by 1,033.2% during the fourth quarter. Millennium Management LLC now owns 156,636 shares of the company's stock worth $594,000 after purchasing an additional 142,814 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of PepGen during the 4th quarter worth approximately $516,000. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of PepGen by 103.1% in the 4th quarter. Bridgeway Capital Management LLC now owns 98,900 shares of the company's stock valued at $375,000 after buying an additional 50,200 shares in the last quarter. Hedge funds and other institutional investors own 58.01% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "buy" rating and issued a $16.00 price objective on shares of PepGen in a research note on Monday, February 24th.
Read Our Latest Analysis on PEPG
PepGen Company Profile
(
Get Free Report)
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
